Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2025 08:00 ET | Source: iBio, Inc.

iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases,...
May 02, 2025 08:00 ET | Source: iBio, Inc.

iBio Reports Fiscal Third Quarter 2025 Financial Results

SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress. ...
April 29, 2025 13:43 ET | Source: iBio, Inc.

iBio Raises $6.2 Million Through Warrant Inducement Transaction

SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody therapies, announces today announced that it has...
April 22, 2025 08:00 ET | Source: iBio, Inc.

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Bio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced a licensing agreement with AstralBio Inc. for a...
April 07, 2025 07:00 ET | Source: iBio, Inc.

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in vivo...
February 19, 2025 16:05 ET | Source: iBio, Inc.

iBio to Begin Trading on the Nasdaq Stock Exchange

SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio’s common stock has been approved for listing...
February 10, 2025 16:05 ET | Source: iBio, Inc.

iBio Reports Fiscal Second Quarter 2025 Financial Results

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, 2024, and provided a corporate update on its progress. ...
January 13, 2025 07:00 ET | Source: iBio, Inc.

iBio Announces New Investments from Board Members and Officers

SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the closing of a private placement offering with...
January 07, 2025 07:00 ET | Source: iBio, Inc.

iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the...
January 02, 2025 07:00 ET | Source: iBio, Inc.

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced the expansion of its cardiometabolic and obesity...

Next Page keyboard_arrow_right